DBV DBV Technologies SA

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023



Monthly information regarding the total number of voting rights and

total number of shares of the Company as of June 30, 2023

 

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

 

 

 

 

Market : NYSE Euronext Paris

ISIN Code: FR 0010417345

 

 

 



Date



 		Total number of shares Total number of voting rights
06/30/202396,250,954 



Total gross of voting rights: 96,250,954



 
 



Total net* of voting rights: 96,100,982



 

 

 

 

* Net total = total number of voting rights attached to shares – shares without voting rights = 96,250,954 –149,972= 96,100,982

 

 

 

 

Attachment



EN
19/07/2023

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces First Subject Screened in COMFORT Toddlers ...

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been act...

3h / 13m 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies annonce le screening du premier sujet de l'étude comp...

DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide. Châtillon, France, le 25 juin (22 :30 CEST) 2025 DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide. Screening du premier sujet à l'Institut de recherche en médecine respiratoire du Michigan, sous la direction du Dr Jeffrey Leflein, investigateur principal.D'autres sites ont été activés et prévoient des...

3h / 13m 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025 Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presen...

June 12, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies participera au prochain congrès EAACI 2025

DBV Technologies participera au prochain congrès EAACI 2025 Châtillon, France, le 12 juin (22:30 CEST) 2025 DBV Technologies participera au prochain congrès EAACI 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT ; CUSIP : 23306J309), une société biopharmaceutique en phase clinique, annonce aujourd'hui sa participation au congrès European Academy of Allergy and Clinical Immunology (EAACI) qui se tiendra du 13 au 16 juin 2025 à Glasgow, au Royaume-Uni. DBV présentera deux posters, organisera un symposium et tiendra un stand dans le hall d'exposition d...

June 12, 2025 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces the Voting Results of its 2025 Combined Gen...

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by t...

June 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch